Who Paid My Doc
Rummana Aslam
Brain Injury Medicine New London, CT Medical Doctor
NPI 1528103983 CMS profile 159641
365 Montauk Ave, New London, CT 06320
General payments
$222
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$60,000
Through program year 2025, Rummana Aslam of New London, CT is reported in the CMS Open Payments database as having received $222 across 2 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $60,000 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $86 | 1 | |
| 2024 | General | $136 | 1 |
Beside peers
- Rummana Aslam
- Brain Injury Medicine median
- Middle half of Brain Injury Medicine
- National median
In program year 2025, general payments to Rummana Aslam were reported at $86. Among 31 Brain Injury Medicine profiles paid that year, the median was $165 and the middle half received between $36 and $391.
Show as a table
| Year | Rummana Aslam | Brain Injury Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $110 | $51–$240 | $163 |
| 2020 | $0 | — | — | $114 |
| 2021 | $0 | $61 | $22–$274 | $132 |
| 2022 | $0 | $79 | $26–$281 | $149 |
| 2023 | $0 | $125 | $49–$275 | $160 |
| 2024 | $136 | $139 | $75–$423 | $164 |
| 2025 | $86 | $165 | $36–$391 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 5 drugsPart D claims
191
Drug cost
$3,673
Branded share of claims
22%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Doxycycline Hyclate | Generic | 49 | $1,084 | |
| Gentamicin Sulfate | Generic | 20 | $920 | |
| Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip | Brand | 42 | $731 | |
| Mupirocin | Generic | 64 | $503 | |
| Clindamycin Phosphate | Generic | 16 | $434 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 30 billing codesPaid by Medicare
$41,759
Medicare patients
185
Services billed
780
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 62% | |
| Ischemic heart disease | 46% | |
| Heart failure | 44% | |
| Atrial fibrillation | 44% | |
| Chronic kidney disease | 44% | |
| Diabetes | 43% | |
| COPD | 34% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
2 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Brain Injury Medicine in Connecticut
Practitioners in the same specialty and state, ranked by reported value.
All Brain Injury Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Connecticut
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.